MedTrace Logo

Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

NCT04624854 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8250

Last updated 2025-12-01

No results posted yet for this study

Summary

This study is a prospective, multicenter, parallel, open-label, randomized, controlled, superiority trial. It is planned to recruit 8,250 patients with multi-vessel disease(MVD), and the patients will be followed-up for at least 12 months after being implanted with a drug-eluting stent (DES) at one of 100 different centers. All patients will be randomly divided into the treatment group and control group on a 1:1 basis, based on a permuted completely randomization.

Conditions

Interventions

DRUG

Clopidogrel and aspirin dual-antiplatelet therapy

Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.

DRUG

Aspirin monotherapy

Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.

Sponsors & Collaborators

  • Chinese Society of Cardiology

    collaborator OTHER

  • Lepu Medical Technology (Beijing) Co., Ltd.

    collaborator INDUSTRY

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • Bo Yu, M.D.,FACC · The Second Affiliated Hospital of Harbin Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-28
Primary Completion
2025-09-23
Completion
2025-09-23

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04624854 on ClinicalTrials.gov